Intuitive Surgical, Inc. (NASDAQ:ISRG) Stock Position Increased by Sage Mountain Advisors LLC

Sage Mountain Advisors LLC lifted its position in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 6.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 1,330 shares of the medical equipment provider’s stock after buying an additional 77 shares during the period. Sage Mountain Advisors LLC’s holdings in Intuitive Surgical were worth $449,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Portside Wealth Group LLC lifted its holdings in shares of Intuitive Surgical by 8.2% during the fourth quarter. Portside Wealth Group LLC now owns 816 shares of the medical equipment provider’s stock valued at $275,000 after purchasing an additional 62 shares during the last quarter. Sequoia Financial Advisors LLC lifted its holdings in shares of Intuitive Surgical by 58.0% during the fourth quarter. Sequoia Financial Advisors LLC now owns 8,315 shares of the medical equipment provider’s stock valued at $2,805,000 after purchasing an additional 3,054 shares during the last quarter. Kades & Cheifetz LLC purchased a new stake in shares of Intuitive Surgical during the fourth quarter valued at $230,000. Blair William & Co. IL lifted its holdings in shares of Intuitive Surgical by 3.1% during the third quarter. Blair William & Co. IL now owns 377,371 shares of the medical equipment provider’s stock valued at $110,302,000 after purchasing an additional 11,400 shares during the last quarter. Finally, Assenagon Asset Management S.A. lifted its holdings in shares of Intuitive Surgical by 21.2% during the third quarter. Assenagon Asset Management S.A. now owns 739,471 shares of the medical equipment provider’s stock valued at $216,140,000 after purchasing an additional 129,194 shares during the last quarter. Institutional investors own 83.64% of the company’s stock.

Intuitive Surgical Price Performance

Shares of ISRG stock opened at $368.93 on Tuesday. Intuitive Surgical, Inc. has a fifty-two week low of $254.85 and a fifty-two week high of $403.76. The stock’s 50-day moving average is $386.57 and its two-hundred day moving average is $344.41. The firm has a market cap of $130.77 billion, a P/E ratio of 66.59, a PEG ratio of 5.69 and a beta of 1.36.

Intuitive Surgical (NASDAQ:ISRG) last issued its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping the consensus estimate of $1.40 by $0.10. The company had revenue of $1.89 billion for the quarter, compared to analyst estimates of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The business’s revenue was up 11.5% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.00 EPS. As a group, research analysts expect that Intuitive Surgical, Inc. will post 4.93 EPS for the current year.

Insider Activity

In other news, CEO Gary S. Guthart sold 24,325 shares of the stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $376.06, for a total transaction of $9,147,659.50. Following the transaction, the chief executive officer now owns 9,425 shares of the company’s stock, valued at approximately $3,544,365.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CEO Gary S. Guthart sold 24,325 shares of the stock in a transaction dated Monday, January 29th. The stock was sold at an average price of $376.06, for a total transaction of $9,147,659.50. Following the transaction, the chief executive officer now owns 9,425 shares of the company’s stock, valued at approximately $3,544,365.50. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, VP Fredrik Widman sold 5,041 shares of the firm’s stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $397.07, for a total value of $2,001,629.87. Following the completion of the sale, the vice president now directly owns 110 shares in the company, valued at approximately $43,677.70. The disclosure for this sale can be found here. In the last quarter, insiders have sold 248,418 shares of company stock valued at $95,927,097. Insiders own 0.80% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have recently commented on the company. Mizuho upped their target price on Intuitive Surgical from $350.00 to $390.00 and gave the company a “neutral” rating in a report on Thursday, January 25th. Piper Sandler upped their target price on Intuitive Surgical from $425.00 to $435.00 and gave the company an “overweight” rating in a report on Friday. Jefferies Financial Group upped their target price on Intuitive Surgical from $365.00 to $375.00 and gave the company a “hold” rating in a report on Friday. Wells Fargo & Company increased their price objective on Intuitive Surgical from $363.00 to $416.00 and gave the stock an “overweight” rating in a research note on Friday, January 19th. Finally, Royal Bank of Canada increased their price objective on Intuitive Surgical from $400.00 to $432.00 and gave the stock an “outperform” rating in a research note on Wednesday, January 24th. Five analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $396.17.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.